{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:54:26Z","timestamp":1777226066857,"version":"3.51.4"},"reference-count":55,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T00:00:00Z","timestamp":1224460800000},"content-version":"vor","delay-in-days":141,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Preventive Cardiology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Cardiovascular disease is understood as a continuum; risk factors induce a pathophysiologic cascade that culminates in end\u2010organ failure. The renin\u2010angiotensin system (RAS) influences multiple aspects of the pathophysiology via hemodynamic and nonhemodynamic effects. Many long\u2010term clinical trials provide overwhelming evidence of benefits of angiotensin\u2010converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) across the cardiovascular continuum, including benefits regarding hypertension, myocardial infarction, stroke, renal disease, and heart failure. Trials also indicate additive or synergistic effects of combination therapy in renal disease and heart failure, a possibility supported by the basic biochemistry of the agents. Discussion of these trials is included in part 1 of this 2\u2010part review. Part 2 of the review will discuss the extensive interaction of the RAS with the cellular and molecular pathophysiology of cardiovascular disease and the cross\u2010continuum effects of ARBs and ACE inhibitors, which raise the possibility that RAS inhibition can offer protection in high\u2010risk patients who do not have symptoms. The benefits of combined ACE inhibitor\/ARB therapy in high\u2010risk patients await confirmation; ongoing clinical research in this area will be discussed.<\/jats:italic>\n          <\/jats:bold> <\/jats:p>","DOI":"10.1111\/j.1751-7141.2008.08435.x","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T13:19:25Z","timestamp":1285247965000},"page":"148-154","source":"Crossref","is-referenced-by-count":7,"title":["Use of Angiotensin\u2010Converting Enzyme Inhibitor\/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in High\u2010Risk Patients: Part 1"],"prefix":"10.1111","volume":"11","author":[{"given":"William J.","family":"Bommer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000035036.22612.2B"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1253"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.179918"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655761"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655688"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000220101.57896.cd"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-006-9799-9"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60242-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/08038020600613480"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/080370502321095285"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80056-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021716"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05012-0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000133730.47372.4c"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"e_1_2_6_18_2","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1731"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09895-1"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000166048.35740.a9"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08090-X"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14739-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1440"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10244-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042167"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2719"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803053381003"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.597"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UKPDS Study Group","year":"1998","journal-title":"BMJ"},{"key":"e_1_2_6_34_2","first-page":"A5","article-title":"Comparative long\u2010term effects of two AT1 receptor blockers on proteinuria in patients with type\u20102 diabetes and overt nephropathy and hypertension: results of the AMADEO trial [abstract]","volume":"9","author":"Bakris G","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042274"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12229-5"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2261"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.05.008"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.04.062"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f35c67"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31804beb59"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00158-X"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2007.6359.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14283-3"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.10.1056"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.022"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2005.07.002"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280ac1533"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.08.001"}],"container-title":["Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7141.2008.08435.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1751-7141.2008.08435.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:22:31Z","timestamp":1696994551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-7141.2008.08435.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1751-7141.2008.08435.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1751-7141.2008.08435.x","archive":["Portico"],"relation":{},"ISSN":["1520-037X","1751-7141"],"issn-type":[{"value":"1520-037X","type":"print"},{"value":"1751-7141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}